Shimomura et al. [18] reported that treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKi) is promising for ocular metastasis of non-small-cell lung cancer harboring an EGFR mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.